Immunogenicity and safety of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and the preS2.
A group of 273 health care workers, at risk of HBV infection, underwent vaccination with recombinant HBsAg produced in mammalian cells and containing protein sequences coded by both the S and pre-S2 regions (Genhevac B). Preliminary results show that a very early pre-S2 response occurred which may be useful in post-exposure prophylaxis. This observation, in addition to reduced influence by the vaccination protocol, provides grounds for optimism in spite of the fact that the efficiency spectrum of this vaccine was not superior to that of recombinant vaccines produced in yeast.
Corradi
M P
MP
Direzione Sanitaria, Ospedale Policlinico Modena, Italy.
Tata
C
C
Marchegiano
P
P
Villa
E
E
De Palma
M
M
Trianni
G
G
Fuiano
L
L
Rompianesi
P
P
Scacchetti
T
T
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D006509:Hepatitis B / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines; D006801:Humans; D011498:Protein Precursors / Q000276:immunology*; D012449:Safety; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D011498:Protein Precursors; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; C050807:presurface protein 2, hepatitis B surface antigen